Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | BAY2701439 |
Synonyms | |
Therapy Description |
BAY2701439 comprises a monoclonal antibody that targets ERBB2 (HER2) conjugated to a chelator complexed with the radioisotope Th 227, which delivers radiation to ERBB2 (HER2-expressing tumors and has potential antitumor activity (Cancer Res 2021;81(13_Suppl):Abstract nr ND07). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
BAY2701439 | BAY-2701439|BAY 2701439|HER2-TTC|227Th Trastuzumab Corixetan | HER2 (ERBB2) Antibody 76 | BAY2701439 comprises a monoclonal antibody that targets ERBB2 (HER2) conjugated to a chelator complexed with the radioisotope Th 227, which delivers radiation to ERBB2 (HER2-expressing tumors and has potential antitumor activity (Cancer Res 2021;81(13_Suppl):Abstract nr ND07). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT04147819 | Phase I | BAY2701439 | A First in Human Study of BAY2701439 to Look at Safety, How the Body Absorbs, Distributes and Excretes the Drug, and How Well the Drug Works in Participants With Advanced Cancer Expressing the HER2 Protein | Completed | USA | GBR | 0 |